Results 301 to 310 of about 810,976 (388)
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem +5 more
wiley +1 more source
News Classification using Natural Language Processing with TF-IDF and Multinomial Naïve Bayes
Nadira Alifia Ionendri +2 more
openalex +2 more sources
Abstract Purpose To investigate the association between best‐corrected visual acuity (BCVA) and quantitative macular fluid volumes, compared to central subfield thickness (CST) in treatment‐naïve and previously treated patients with active neovascular age‐related macular degeneration (nAMD).
Anna Eidenberger +15 more
wiley +1 more source
ABSTRACT This study investigates the use of otolith shape analysis for species identification and size estimation in Ariopsis felis and Bagre marinus, based on 181 modern otoliths obtained from a scientific collection and recent sampling in the coastal regions of Campeche and Yucatán, as well as 39 archaeological otoliths corresponding to the Early ...
Ariana Solis‐Gómez +7 more
wiley +1 more source
Comparison of Support Vector Machine, Naïve Bayes and Logistic Regression for Assessing the Necessity for Coronary Angiography. [PDF]
Golpour P +8 more
europepmc +1 more source
Corruption Detection Through Textual Analysis: Evidence From Eurozone Banks
ABSTRACT This research investigates the disclosure of banking institutions by analyzing their annual reports to identify the determinants capable of signaling possible corruption scandals. A textual analysis was conducted on the financial reports of 42 Eurozone banks from the period 2013 to 2022.
Rodolfo Damiano +3 more
wiley +1 more source
Left panel: Scheme of the XPAG‐immune thrombocytopenia trial. The dexamethasone (DEX) arm consisted of DEX 40 mg/day for days 1–4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag (ETB) + DEX received eltrombopag in combination with a short course of high‐dose DEX beginning on
Paul Schmidt‐Barbo +24 more
wiley +1 more source

